Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Glaxosmithkline Plc (GSK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 98,230,024
  • Shares Outstanding, K 2,479,930
  • Annual Sales, $ 38,904 M
  • Annual Income, $ 1,974 M
  • 36-Month Beta 0.87
  • Price/Sales 2.53
  • Price/Cash Flow 10.32
  • Price/Book 23.88

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 0.87
  • Number of Estimates 3
  • High Estimate 0.88
  • Low Estimate 0.86
  • Prior Year 0.85
  • Growth Rate Est. (year over year) +2.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.88 +7.89%
on 10/12/18
40.90 -0.07%
on 10/19/18
+1.32 (+3.34%)
since 09/19/18
3-Month
37.88 +7.89%
on 10/12/18
42.32 -3.43%
on 07/20/18
+0.18 (+0.44%)
since 07/19/18
52-Week
34.52 +18.40%
on 12/06/17
42.36 -3.52%
on 06/14/18
-0.23 (-0.56%)
since 10/19/17

Most Recent Stories

More News
Puma Biotech (PBYI) Rides High on Robust Nerlynx Performance

Puma Biotech (PBYI) focuses on improving sales of its flagship and the only approved product Nerlynx. The drug's label expansion programs also appear promising.

PBYI : 42.18 (-3.19%)
LLY : 111.92 (-1.23%)
RHHBY : 30.5950 (+2.55%)
GSK : 40.87 (+3.18%)
United States Influenza Vaccines Market to 2025 with Seqirus, Sanofi Pasteur, GlaxoSmithKline (GSK) and AstraZeneca Set to Dominate

The "United States Influenza Vaccines Market Report, Analysis and Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

GSK : 40.87 (+3.18%)
NeuroMetrix Reports Q3 2018 Financial Results

NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and business highlights for the quarter ended September 30, 2018.

NURO : 1.24 (-2.36%)
GSK : 40.87 (+3.18%)
Emergent Completes Acquisition of Narcan Maker Adapt Pharma

Emergent (EBS) wraps up the buyout of Adapt Pharma for $735 million. This strategic move will add the latter's popular Narcan nasal spray to its portfolio.

GNMSF : 139.4500 (+2.35%)
EBS : 60.74 (-1.56%)
GSK : 40.87 (+3.18%)
SNY : 44.57 (+0.27%)
Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal

AbbVie (ABBV) signs licensing deal with Sandoz, the generic arm of Novartis. J&J (JNJ) gains FDA approval for label expansion of its blood thinner, Xarelto.

CGEN : 3.64 (-4.21%)
JNJ : 139.05 (-0.32%)
LLY : 111.92 (-1.23%)
NVS : 87.19 (+1.10%)
ABBV : 87.97 (-2.15%)
GSK : 40.87 (+3.18%)
BMY : 54.30 (-3.00%)
Excellent Growth Seen in "Post-Operative Pain Management Market" by 2023 - Competitive Landscape and Revenue Status by Most Prominent Players

VRX.TO : 30.80 (-3.33%)
ENDP : 17.53 (-0.06%)
LLY : 111.92 (-1.23%)
BAX : 69.46 (-1.43%)
NVS : 87.19 (+1.10%)
GSK : 40.87 (+3.18%)
Novartis Presents Positive Data on Sickle Cell Disease Drug

Novartis (NVS) announces positive results from a post hoc analysis of the phase II study, SUSTAIN, on pipeline candidate, crizanlizumab, being published in the American Journal of Hematology.

ONCE : 47.76 (-4.23%)
NVS : 87.19 (+1.10%)
GSK : 40.87 (+3.18%)
BMY : 54.30 (-3.00%)
BioLabs@CIC Philadelphia Launches Free Science Insights series with "Insights into Immuno-Oncology: Fighting Cancer from Within" Event, Wednesday October 10th, from 4 to 6:30 pm

BioLabs@CIC Philadelphia will launch its Science Insights series at the new QUORUM Center with Insights into Immuno-Oncology: Fighting Cancer from Within. Free, and open to the public, learn how immunotherapy...

GSK : 40.87 (+3.18%)
Merck Reports Positive Efficacy Data from Phase III HIV Study

Merck (MRK) reports positive data from the phase III DRIVE-AHEAD study, evaluating Delstrigo in treatment-naive adults with HIV-1 infection.

MRK : 72.35 (+0.19%)
GILD : 73.27 (-1.21%)
GSK : 40.87 (+3.18%)
BMY : 54.30 (-3.00%)
Gilead Announces Positive Data From Ongoing Biktarvy Study

Gilead (GILD) reports positive data from an ongoing late stage study on HIV regimen, Biktarvy at 96 weeks.

MRK : 72.35 (+0.19%)
ABBV : 87.97 (-2.15%)
GILD : 73.27 (-1.21%)
GSK : 40.87 (+3.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade GSK with:

Business Summary

GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central...

See More

Key Turning Points

2nd Resistance Point 41.25
1st Resistance Point 41.06
Last Price 40.87
1st Support Level 40.52
2nd Support Level 40.17

See More

52-Week High 42.36
Last Price 40.87
Fibonacci 61.8% 39.37
Fibonacci 50% 38.44
Fibonacci 38.2% 37.51
52-Week Low 34.52

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar